What is HC Wainwright’s Estimate for HRTX Q1 Earnings?

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Heron Therapeutics in a research report issued to clients and investors on Thursday, February 26th. HC Wainwright analyst B. Folkes anticipates that the biotechnology company will post earnings per share of ($0.03) for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Heron Therapeutics’ Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.00 EPS, FY2027 earnings at $0.14 EPS, FY2028 earnings at $0.39 EPS, FY2029 earnings at $0.44 EPS and FY2030 earnings at $0.55 EPS.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. The business had revenue of $40.59 million for the quarter, compared to analysts’ expectations of $39.53 million.

Other equities analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Thursday, January 22nd. Jefferies Financial Group restated a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Heron Therapeutics has a consensus rating of “Hold” and a consensus price target of $4.50.

Heron Therapeutics Trading Up 11.1%

Shares of HRTX stock opened at $1.20 on Friday. The stock has a market capitalization of $220.03 million, a PE ratio of -13.33 and a beta of 1.25. Heron Therapeutics has a 1-year low of $1.00 and a 1-year high of $2.68. The business has a 50-day moving average of $1.30 and a 200 day moving average of $1.27. The company has a debt-to-equity ratio of 19.89, a current ratio of 2.56 and a quick ratio of 1.78.

Institutional Investors Weigh In On Heron Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of HRTX. ProShare Advisors LLC increased its position in shares of Heron Therapeutics by 23.4% during the second quarter. ProShare Advisors LLC now owns 31,368 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 5,953 shares during the period. SG Americas Securities LLC lifted its holdings in Heron Therapeutics by 39.1% in the fourth quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock worth $32,000 after buying an additional 6,858 shares during the period. Richmond Brothers Inc. boosted its position in Heron Therapeutics by 1.8% during the 2nd quarter. Richmond Brothers Inc. now owns 554,469 shares of the biotechnology company’s stock valued at $1,148,000 after acquiring an additional 9,568 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Heron Therapeutics by 5.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 241,048 shares of the biotechnology company’s stock worth $499,000 after acquiring an additional 11,716 shares during the period. Finally, B. Riley Wealth Advisors Inc. purchased a new position in shares of Heron Therapeutics during the 2nd quarter worth approximately $26,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Heron Therapeutics

Here are the key news stories impacting Heron Therapeutics this week:

• Positive Sentiment: Q4 results topped estimates: Heron reported EPS of ($0.02) vs. a ($0.03) consensus and revenue of $40.6M vs. $39.5M expected — evidence of accelerating sales. Heron News Release
• Positive Sentiment: Company issued upbeat FY‑2026 revenue guidance of $173M–$183M (above consensus $171.8M) and adjusted EBITDA guidance of $10M–$20M — guidance that supports the bullish near‑term narrative. Guidance in Press Release
• Positive Sentiment: Analyst support: HC Wainwright maintained a Buy rating and a $6 price target, reflecting conviction in longer‑term upside despite current low share price — a supportive brokerage stance for investor sentiment.
• Neutral Sentiment: Management color and presentation materials released (earnings call, slide deck) provide detail on drivers — ZYNRELEF and APONVIE were cited as the growth engines; investors can review the call for execution updates. Earnings Call Highlights
• Neutral Sentiment: Market coverage: Several outlets summarized the quarter and guidance (Zacks, WTOP) — useful for quick third‑party reads but not new primary data. Zacks Summary
• Negative Sentiment: HC Wainwright trimmed FY‑2027–FY‑2029 (and FY‑2028) EPS forecasts modestly (e.g., FY‑2029 cut to $0.44 from $0.48) — a signal that while near‑term performance is solid, analysts are moderating longer‑term margin/profit expectations.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.